Literature DB >> 12907625

Human CD4+ CD25+ regulatory T cells suppress NKT cell functions.

Takeshi Azuma1, Tsuyoshi Takahashi, Atsushi Kunisato, Tadaichi Kitamura, Hisamaru Hirai.   

Abstract

CD4+CD25+ regulatory T cells play an important role in peripheral tolerance. These cells have been reported to be capable of suppressing the response of CD4+CD25- T cells in vitro. The depletion of these cells evokes effective immune responses to tumor cells in vivo. In this study, we demonstrate that CD4+CD25+ T cells also suppress all subsets of Valpha24+NKT cells (Valpha24+CD4-CD8- double negative, Valpha24+CD4+, and Valpha24+CD8+) in both proliferation and cytokine production [IFN-gamma, interleukin-4 (IL-4), IL-13, and IL-10]. This suppression is mediated by cell-to-cell contact but not by a humoral factor or the inhibition of antigen-presenting cells. Moreover, the cytotoxic activity of Valpha24+NKT cells against some tumor cell lines is suppressed by CD4+CD25+ T cells. This finding is important in developing an effective immunotherapy for cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12907625

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  64 in total

1.  Reduced frequency of NKT-like cells in patients with progressive chronic lymphocytic leukemia.

Authors:  Farhad Jadidi-Niaragh; Mahmood Jeddi-Tehrani; Bita Ansaripour; Seyed Mohsen Razavi; Ramazan Ali Sharifian; Fazel Shokri
Journal:  Med Oncol       Date:  2012-06-06       Impact factor: 3.064

Review 2.  Contrasting effects of TNF and anti-TNF on the activation of effector T cells and regulatory T cells in autoimmunity.

Authors:  Xin Chen; Joost J Oppenheim
Journal:  FEBS Lett       Date:  2011-04-15       Impact factor: 4.124

Review 3.  Going both ways: immune regulation via CD1d-dependent NKT cells.

Authors:  Dale I Godfrey; Mitchell Kronenberg
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

4.  Identification of a unique double-negative regulatory T-cell population.

Authors:  Byung O Lee; Joyce E Jones; Cory J Peters; David Whitacre; Lars Frelin; Janice Hughes; Won-Keun Kim; David R Milich
Journal:  Immunology       Date:  2011-12       Impact factor: 7.397

5.  Effective modulation of CD4(+)CD25 (+high) regulatory T and NK cells in malignant patients by combination of interferon-α and interleukin-2.

Authors:  Guangxian Liu; Wuwei Yang; Mei Guo; Xiaoqing Liu; Naixiang Huang; Dingfeng Li; Zefei Jiang; Wenfeng Yang; Weijing Zhang; Hang Su; Zhiqing Liu; Tieqiang Liu; Dongmei Wang; Shan Huang; Bo Yao; Qiuhong Man; Lijuan Qiu; Xuedong Sun; Yuying Sun; Bing Liu
Journal:  Cancer Immunol Immunother       Date:  2012-06-22       Impact factor: 6.968

Review 6.  Immunotherapeutic strategies targeting natural killer T cell responses in cancer.

Authors:  Susannah C Shissler; Dominique R Bollino; Irina V Tiper; Joshua P Bates; Roshanak Derakhshandeh; Tonya J Webb
Journal:  Immunogenetics       Date:  2016-07-08       Impact factor: 2.846

7.  Suppression of natural killer cell-mediated bone marrow cell rejection by CD4+CD25+ regulatory T cells.

Authors:  Isabel Barao; Alan M Hanash; William Hallett; Lisbeth A Welniak; Kai Sun; Doug Redelman; Bruce R Blazar; Robert B Levy; William J Murphy
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-27       Impact factor: 11.205

8.  Circulating CD4+ CD25+ regulatory T cells correlate with chronic hepatitis B infection.

Authors:  Guoping Peng; Shuping Li; Wei Wu; Zhen Sun; Yiqiong Chen; Zhi Chen
Journal:  Immunology       Date:  2007-08-31       Impact factor: 7.397

Review 9.  CD25+ CD4+ regulatory T-cells in cancer.

Authors:  David C Linehan; Peter S Goedegebuure
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

10.  An alpha-galactosylceramide C20:2 N-acyl variant enhances anti-inflammatory and regulatory T cell-independent responses that prevent type 1 diabetes.

Authors:  D Ly; R Tohn; B Rubin; H Blumenfeld; G S Besra; N Veerapen; S A Porcelli; T L Delovitch
Journal:  Clin Exp Immunol       Date:  2009-12-15       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.